Dr. Fitzgerald joined Alnylam in 2005 as Associate Director of Research and has served in roles of increasing responsibility since that time, including as Head of Delivery Technologies and Head of New Program Discovery and Early-Stage Clinical Programs. He now oversees research and early development activities across diseases and therapeutic areas. Dr. Fitzgerald spearheaded many of the discoveries and technological advances that led to the first phase of the RNAi Revolution, and he is listed on many of Alnylam’s key patents. He was instrumental in translating the discovery of RNAi into an innovative class of medicines and believes that Alnylam has the opportunity—and responsibility—to bring its pioneering technology to many more patients. Prior to 2005, Dr. Fitzgerald was at Bristol-Myers Squibb for 7 years after completing a postdoctoral fellowship in oncology at Harvard Medical School. He received his Bachelor of Science in genetics from Cornell University and his doctorate in molecular biology from Princeton University/Columbia Medical School.